Skip to main content

Market access for medical technologies in Denmark

A brief overview of key market access pathways and challenges for medical devices, in-vitro diagnostic tests in Denmark

sdcd

Key topics

There are three key themes describing market access for medical technologies in Denmark: 

  • Reimbursement: payment mechanism via the DRG-adjusted budget system
  • Funding: national recommendations from the Health Technology Council
  • Health technology assessment: obtaining recommendations from the national and local HTA bodies
dcdsz

Reimbursement

Denmark uses the DkDRG system, but hospital revenue from the DRGs accounts for only about 20%. Hospital care is predominantly funded via a global budget mechanism, which is mostly calculated based on actual costs incurred by the hospitals (differences in calculation methodology among regions may exist). 

However, all inter-regional care is reimbursed on a case-by-case basis via the DRG system. Therefore, the role of DRG is higher for procedures, which are concentrated only in several hospitals across the country and which provide care for patients from other Danish regions. 

DRGs are determined by the combination of a procedure code (SKS) and a diagnosis code (ICD-10). The SKS nomenclature and the DkDRG system are maintained by the Health Data Authority. 

dcdx

Funding

Denmark has no nationally defined list of health benefits which are guaranteed to the Danish population. Decisions on which treatment methods to use and which new technologies to introduce are made by the hospitals.

Danish regions have a system to collaborate on the introduction of medical technologies and to enable equal access, cost-effective and efficient use of medical technologies in the country. In this framework, technologies are evaluated on the national level by the Health Technology Council, which provides recommendations for the adoption of novel technologies to payers (Regions) and healthcare providers. 

dcxsxsx

Health technology assessment

HTA is performed on the national level (as part of the evaluations by the Health Technology Council) or on the regional and local levels (two organizations have limited activity in the Med Tech space). 

dcvcxc

Specifics for IVD tests

There is no specific reimbursement framework for in-vitro diagnostic tests. IVD tests are funded using a global budget principle as part of the laboratory funding.

MTRC has experience with more than 143 projects in Denmark

News and insights

01 Jan 2024

New SKS procedure codes from January 1, 2024 in Denmark

The Danish Health Data Authority quarterly updates the Health Care Classification System (SKS). In December 2023, the latest code changes were published to come into force on January 1, 2024. Nine new surgical procedure codes and four new medical (MedTech-related) procedure codes concerning cardiovascular, gastrointestinal, interventional radiology, men’s health, peripheral vascular, radiotherapy, and dermatology were introduced.
27 Dec 2023

Funding of 500 million DKK for home treatment with digital solutions in Denmark

In December 2023, the Government, Danish Regions, and Municipalities (KL) signed an agreement providing 500 million DKK from 2023 to 2028 to promote the spread of digital treatment services. This will include technologies for home monitoring and targeted control for patients with chronic diseases (such as diabetes, COPD, and heart failure), thus reducing the number of physical check-ups and preventing unnecessary hospitalizations.
30 Nov 2023

Additional governmental funding for cancer care in Denmark

The Danish government granted the Danish Regions an additional 300 million DKK to strengthen cancer care in 2024. From 2025, the government confirmed permanent annual funding of 600 million DKK for “Cancer Plan V”, expected to be published by Autumn 2024.

Get in touch

Contact us to discuss your needs and learn about our services